Emyria Limited

Equities

EMD

AU0000073645

Healthcare Facilities & Services

Market Closed - Australian S.E. 11:44:21 2024-03-27 pm EDT 5-day change 1st Jan Change
0.059 AUD 0.00% Intraday chart for Emyria Limited -6.35% +13.46%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Emyria Limited Reports Earnings Results for the Half Year Ended December 31, 2023 CI
Emyria Secures AU$2.5 Million R&D Tax Rebate for Fiscal Year 2023 MT
Australian Medical Regulator Grants ‘Authorized Prescriber’ Status to Emyria’s Specialist Psychiatrist; Shares Soar 19% MT
Emyria Limited Appoints Greg Hutchinson as Director CI
PharmAla Biotech and Filament Health Announce Release of Second Batch of GMP MDMA Capsules MT
Emyria Limited Announces Board Changes CI
Emyria Secures Canadian Regulatory Clearance to Import MDMA to Australia; Shares Fall 3% MT
Emyria Begins MDMA Therapy Trials on PTSD Patients MT
Emyria Secures Local Supply of Psychedelic Drug for Upcoming Trial; Shares Rise 3% MT
Emyria Completes Pax Center Acquisition MT
Emyria Limited completed the acquisition of The Pax Centre from Glenroyale Pty Ltd and Vivo (WA) Pty Ltd. CI
Emyria Limited Reports Earnings Results for the Full Year Ended June 30, 2023 CI
Emyria Limited Announces Strategic Board Transition CI
Emyria to Start Ketamine-Assisted Therapy Program for Depression MT
Emyria Enrolls First Patient for Psychedelics-Assisted Trial MT
Emyria to Acquire Psychological Trauma Care Firm MT
Emyria Limited signed an agreement to acquire The Pax Centre from Glenroyale Pty Ltd for AUD 1.7 million. CI
Hawkish Central Bank, Muted Growth Concerns Send Australian Shares to Three-Day Losing Streak MT
Emyria Secures Ethics Approval for Psychedelics-Assisted Trial; Shares Jump 8% MT
Emyria to Raise AU$2.5 Million Via Share Placement MT
Emyria Launches High-Potency Cannabidiol Capsule Product; Shares Rise 6% MT
Emyria, PAX Centre Extend Collaboration to Develop Care Model for Psilocybin-assisted Therapy; Shares Rise 3% MT
Australian Shares Continue to Rise as RBA Holds Rates MT
Emyria Signs Deal to Commercialize Cannabidiol Medication; Shares Fall 5% MT
Emyria Advances Patient Recruitment, Initial Dosing for Phase Three Anxiety Trial MT
Chart Emyria Limited
More charts
Emyria Limited is an Australia-based clinical services and drug development company. The Company is focused on developing patient outcomes in neuroscience and mental health through its clinical service delivery, proprietary real-world data (RWD), and drug discovery & development. It delivers evidence-based and emerging therapies for mental health and other unmet needs through its Emerald Clinics and the Pax Centre. Emerald Clinics specializes in providing treatments for patients with complex and chronic conditions. The Pax Centre specializes in treating individuals grappling with the psychological impacts of traumatic experiences. Through its advanced data platform operated by Palantir, the Company collects robust and ethically sourced real-world data to improve its care models and support its distinct therapy and drug development initiatives. The Company is also developing several proprietary ultra-pure cannabinoid dose forms and advancing them towards registration, such as EMD-RX5.
More about the company
  1. Stock
  2. Equities
  3. Stock Emyria Limited - Australian S.E.
  4. News Emyria Limited
  5. Emyria Begins Dosing Patients for Phase 1 Clinical Trial for Cannabidiol Drug